Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
about
Conserved loop cysteines of vitamin K epoxide reductase complex subunit 1-like 1 (VKORC1L1) are involved in its active site regenerationPharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumonThe allele frequency of CYP2C9 and VKORC1 in the Southern Khorasan population.Genetic risk factors for major bleeding in patients treated with warfarin in a community setting.Determinants of the over-anticoagulation response during warfarin initiation therapy in Asian patients based on population pharmacokinetic-pharmacodynamic analysesGenotype and risk of major bleeding during warfarin treatment.Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting.Evaluation of warfarin resistance using transcription activator-like effector nucleases-mediated vitamin K epoxide reductase knockout HEK293 cells.Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms.Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches.VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.Long-term outcomes of elderly patients with CYP2C9 and VKORC1 variants treated with vitamin K antagonists.Influence of VKORC1 gene polymorphisms on the effect of oral vitamin K supplementation in over-anticoagulated patients.The Influence of CYP2C9 and VKORC1 Gene Polymorphisms on the Response to Warfarin in Egyptians.
P2860
Q24337424-1744707D-9519-41AD-92E7-5A98E8783F77Q27006860-1E93BA26-56F4-44AE-B67F-B2EF756C8FE9Q33782314-75CE2E35-9392-4BEC-8E82-1F6F229B190AQ33792352-08C818F6-4453-4107-995A-537C640E8C1AQ34078825-FF59A813-8FAB-4F06-A6DE-D939ACFCD0B8Q35006973-2E44CB2F-E364-4863-9C7C-509D19FFFC7EQ35772034-4BFE71BD-6AC0-4661-9775-E9344BA40C32Q37100171-FD350B23-70F0-4BC9-B2F9-2F8223421244Q38078754-50E146A5-3807-4059-87D0-252C8C07BF03Q45362158-A02512B2-7264-4F9E-858A-BF4D1DCA4C9FQ47345423-72819D22-7CB6-4B33-8D28-B78F7875BF17Q47402745-C773CA07-32AB-494F-BFF9-E50AF06D31B4Q47728750-4E0226BB-0047-4A24-9622-3DA4FA0989B5Q50903331-F09D47CF-8240-4A61-BDA4-CC98162B3596Q53695415-70D190B8-37F3-4C36-9002-F18FE6162AB4
P2860
Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Polymorphisms in VKORC1 have m ...... io control and bleeding rates.
@en
Polymorphisms in VKORC1 have m ...... io control and bleeding rates.
@nl
type
label
Polymorphisms in VKORC1 have m ...... io control and bleeding rates.
@en
Polymorphisms in VKORC1 have m ...... io control and bleeding rates.
@nl
prefLabel
Polymorphisms in VKORC1 have m ...... io control and bleeding rates.
@en
Polymorphisms in VKORC1 have m ...... io control and bleeding rates.
@nl
P2093
P2860
P1476
Polymorphisms in VKORC1 have m ...... io control and bleeding rates.
@en
P2093
Anne Marie Etherington
Dairena Gaffney
Kirstin Lund
Patrick Tansey
Richard Spooner
P2860
P304
P356
10.1111/J.1365-2141.2012.09150.X
P407
P577
2012-05-10T00:00:00Z